Spinal abnormalities in neurofibomatosis type 1
1 型神经纤维瘤病的脊柱异常
基本信息
- 批准号:7253117
- 负责人:
- 金额:$ 34.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2011-03-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAddressAreaBone DensityBone ResorptionBritish ColumbiaChildClinicalClinical ManagementClinical ResearchConditionDefectDeformityDevelopmental Bone DiseasesDiseaseDysplasiaFutureGoalsHereditary DiseaseIncidenceIndividualMagnetic Resonance ImagingMeasuresMeningoceleMuscleNatural HistoryNeurofibromatosis 1OutcomeOutcome StudyPathogenesisPathological DilatationPatientsPediatric HospitalsPeripheralPrognostic FactorRecording of previous eventsRecruitment ActivityRotationScallopScreening procedureSkeletal systemSpinalSpinal CanalSpinal CordTestingTherapeutic Clinical TrialThickUniversitiesUtahVertebral columnWingX-Ray Computed Tomographybonebone healthcohortcrosslinkimprovedindexinglong boneneurofibromaprognosticrib bone structurescoliosisspine bone structuretoolurinaryvertebra body
项目摘要
DESCRIPTION (provided by applicant): Neurofibromatosis type 1 (NF1) is a common genetic disorder with a high degree of variability of clinical expression, including skeletal abnormalities in over 1/3 of patients. This disorder is associated with spinal abnormalities, long bone dysplasia, and sphenoid wing dysplasia. These osseous manifestations are unpredictable, and the pathogenesis, natural history, and clinical outcome remain relatively obscure. The spinal abnormalities are varied and include scoliosis (common and dystrophic forms), neurofibromas, dural ectasias, meningoceles, and vertebral defects. The primary objectives of this clinical study are to determine the incidence and clinical history of NF1-related spinal abnormalities in a prepubertal cohort of 120 children with NF1 over 3 years. Secondary objectives are to determine the efficacy of various radiographic screening tools as predictors for dystrophic scoliosis. These goals will be accomplished in 3 specific aims. Aim 1 is to identify associations of spinal cord dural ectasias, spinal neurofibromas, and meningoceles with dysplastic osseous abnormalities and dystrophic scoliosis. Spine radiographs and MRI will be used to test the hypothesis that NF1 patients with certain manifestations are more likely to develop dystrophic scoliosis. Aim 2 is to define the clinical history and short-term outcome of dystrophic scoliosis and spine abnormalities with respect to various radiographic indices. It tests the hypothesis that there are quantitative differences in vertebral scalloping and spinal canal and vertebral body cross-sectional areas when there is an associated additional dystrophic abnormality and these differences are prognostic indicators for dystrophic scoliosis. Aim 3 is to determine the differences in bone health variables between NF1 patients and individuals without NF1, and between NF1 individuals without dystrophic scoliosis versus NF1 individuals who develop dystrophic scoliosis. Dual energy x-ray absorptiometry (DXA) and peripheral quantitative computerized tomography (pQCT) will be used to test the hypothesis that there-are subtle bone abnormalities of bone mineral density, bone area, bone mass, muscle-to-bone ratios, and cortical thickness in NF1. Urinary Dyridinium cross-links will be measured to detect differences in bone resorption. Spinal abnormalities in NF1 are not well understood, and dystrophic scoliosis is a highly morbid condition. This proposal will identify variables in patients with NF1 as prognostic factors for dystrophic scoliosis to improve clinical management.
描述(申请人提供):神经纤维瘤病1型(NF1)是一种常见的遗传性疾病,具有高度的临床表现变异性,包括超过三分之一的患者的骨骼异常。这种疾病与脊柱异常、长骨发育不良和蝶骨翅膀发育不良有关。这些骨性表现是不可预测的,其发病机制、自然病史和临床结果仍然相对不明。脊柱异常多种多样,包括脊柱侧弯(常见形式和营养不良形式)、神经纤维瘤、硬膜扩张症、脑膜膨出和脊椎缺陷。这项临床研究的主要目标是确定3年来120名患有NF1的青春期前儿童中与NF1相关的脊柱异常的发生率和临床病史。次要目标是确定各种放射学筛查工具作为营养不良性脊柱侧弯预测指标的有效性。这些目标将通过三个具体目标来实现。目的1是确定脊髓硬膜扩张症、脊髓神经纤维瘤和脑膜膨出与发育不良骨性异常和营养不良性脊柱侧弯的关系。脊柱X光片和核磁共振将被用来检验这一假设,即具有某些症状的NF1患者更有可能发展为营养不良性脊柱侧弯。目的2是根据不同的放射学指标,确定营养不良性脊柱侧弯和脊柱异常的临床病史和短期预后。它验证了这样的假设,即当存在与之相关的额外营养不良异常时,椎体横截面积、椎体横截面积和椎体横截面积存在数量上的差异,这些差异是营养不良脊柱侧弯的预后指标。目的3是确定NF1患者与非NF1患者、无营养不良脊柱侧凸的NF1患者与发生营养不良脊柱侧凸的NF1患者之间的骨健康变量的差异。将使用双能X线骨密度仪(DXA)和外周定量计算机断层扫描(PQCT)来验证NF1存在骨密度、骨面积、骨量、肌骨比和皮质厚度的细微骨异常的假设。将测量尿镝的交联度,以检测骨吸收的差异。NF1的脊柱异常还不是很清楚,营养不良性脊柱侧弯是一种高度病态的情况。这项建议将确定NF1患者的变量作为营养不良性脊柱侧凸的预后因素,以改善临床治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID H. VISKOCHIL其他文献
DAVID H. VISKOCHIL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID H. VISKOCHIL', 18)}}的其他基金
CLINICAL TRIAL: MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY
临床试验:接受酶替代疗法的 MPS II 患者
- 批准号:
7718513 - 财政年份:2008
- 资助金额:
$ 34.01万 - 项目类别:
MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY
接受酶替代治疗的 MPS II 患者
- 批准号:
7604971 - 财政年份:2007
- 资助金额:
$ 34.01万 - 项目类别:
MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY
接受酶替代治疗的 MPS II 患者
- 批准号:
7376481 - 财政年份:2006
- 资助金额:
$ 34.01万 - 项目类别:
Spinal abnormalities in neurofibomatosis type 1
1 型神经纤维瘤病的脊柱异常
- 批准号:
7590467 - 财政年份:2006
- 资助金额:
$ 34.01万 - 项目类别:
Spinal abnormalities in neurofibomatosis type 1
1 型神经纤维瘤病的脊柱异常
- 批准号:
7409973 - 财政年份:2006
- 资助金额:
$ 34.01万 - 项目类别:
Spinal abnormalities in neurofibomatosis type 1
1 型神经纤维瘤病的脊柱异常
- 批准号:
7805420 - 财政年份:2006
- 资助金额:
$ 34.01万 - 项目类别:
Spinal abnormalities in neurofibomatosis type 1
1 型神经纤维瘤病的脊柱异常
- 批准号:
7038788 - 财政年份:2006
- 资助金额:
$ 34.01万 - 项目类别:
RECOMBINANT HUMAN ALPHA-L IDURONIDASE IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS I
重组人 α-L 艾杜糖醛酸酶治疗 I 型粘多糖病患者
- 批准号:
7201409 - 财政年份:2005
- 资助金额:
$ 34.01万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 34.01万 - 项目类别:
Research Grant














{{item.name}}会员




